Subcommittee on WGS and Phenotypic AST

The EUCAST subcommittee on the role of whole genome sequencing (WGS) in antimicrobial susceptibility testing (AST) was first established in 2015. The chair was Neil Woodford and co-chairs were Matthew Ellington and Oskar Ekelund. 

Findings and the conclusions of the first subcommittee, published in 2017, can be found here.

EUCAST has now re-established the subcommittee.

The subcommittee was re-established in 2023/24 under the leadership of Antonio Oliver and co-chair Örjan Samuelsen, with Scientific Secretary Carla Lopez-Causape. The subcommittee is tasked with updating the EUCAST document and opinion on the role of WGS in AST. 

  Antonio Oliver

Antonio Oliver

Chair
Spain
  Ørjan Samuelsen

Ørjan Samuelsen

Co-Chair
Norway
  Carla Lopez-Causape

Carla Lopez-Causape

Scientific Secretary
Spain

Subcommittee Members

   

Valeria Bortolaia

Denmark

Kat Holt

United Kingdom

Thierry Naas

France

Mike Brouwer

Netherlands

Katie Hopkins

United Kingdom

Spyros Pournaras

Greece

Rafael Cantón

Spain

Ben Howden

Australia

Etienne Ruppé

France

Adrian Egli

Switzerland

Katy Jeannot

France

Thomas Schön

Sweden

Christian Giske

Sweden

Gunnar Kahlmeter

Sweden

Nicole Stoesser 

United Kingdom

Yonatan Grad

United States

Claudio Köser

United Kingdom

John Turnidge

Australia

Axel Hamprecht

Germany

Amy Mathers

United States

Guido Werner

Germany

Susanne Haussler

Germany

Frank Møller Aarestrup

Denmark

Gerry Wright

Canada

  • to perform a review of the literature describing the role of WGS in antimicrobial susceptibility testing (AST) of bacteria;
  • to assess the sensitivity and specificity of WGS compared with standard phenotypic AST;
  • to consider how WGS for AST may be applied in clinical microbiology laboratories and the likely implications for phenotypic and other genotypic methods in use;
  • to consider the epidemiological implications of using WGS;
  • to consider the clinical implications of WGS for the selection of antimicrobial therapy;
  • (to consider the principles of how the results of WGS for AST could be presented to clinical users;
  • to describe the drivers and barriers to routine use of WGS.

Contact

Looking for more information? Get in touch with an EUCAST representative today!

Contact form